pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress

Sponsor
NYU Langone Health (Other)
Overall Status
Completed
CT.gov ID
NCT03028675
Collaborator
(none)
4
1
15.3
0.3

Study Details

Study Description

Brief Summary

Twenty subjects (10 patients and 10 age-matched control volunteers) will be recruited for this study. MRI scans will take place on a 3T MRI Scanner (Skyra or Prisma, Siemens Medical Solutions) located at The NYU Center for Biomedical Imaging. MRI scans will consist of a 1-hour brain scan for both patients and controls. In the first 6 months of the study, investigators will develop and test a uMT-based APT imaging for brain tissue pH measurement and use a hypercapnia paradigm to validate the tissue pH changes between breathing room air and 5% CO2 (by increasing tissue acidity) inhalation. With implementation of hypercapnia MRI, pH-weighted imaging will be validated for its robustness and reproducibility.

Condition or Disease Intervention/Treatment Phase
  • Other: MRI Scan

Detailed Description

The contrast agent (Gd-DTPA, Gadavist) will be injected intravenously (IV) in the arm (patients only). The IV will be inserted by qualified medical professional at CBI. This contrast agent will be standard dose in accordance with its FDA approved labeling and dosing. Controls will NOT be administered the contrast agent.

Study Design

Study Type:
Observational
Actual Enrollment :
4 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress
Actual Study Start Date :
May 1, 2017
Actual Primary Completion Date :
Aug 10, 2018
Actual Study Completion Date :
Aug 10, 2018

Arms and Interventions

Arm Intervention/Treatment
Multiple Sclerosis

Other: MRI Scan
MRI scans will consist of a 1-hour brain scan for both patients and controls.

Healthy Volunteer

10 age-matched control volunteers

Other: MRI Scan
MRI scans will consist of a 1-hour brain scan for both patients and controls.

Outcome Measures

Primary Outcome Measures

  1. pH measurements [20 Minutes]

    The pH will be estimated based on the calibration methods of quantification of exchange as a function of saturation time (QUEST)32 and its ratiometric analysis (QUESTRA) 33.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy male or female non-MS control volunteers
Exclusion Criteria:
  • Medically unstable or with cardiac, pulmonary, hematological, renal, or hepatic dysfunction.

  • Current or past DSM-IV diagnosis of major depression, bipolar and psychotic disorders.

  • Contraindications for MRI, including

  • Intracranial clips

  • Metal implants

  • External metallic devices/objects/clips within 10mm of the head

  • Suspected or confirmed metal in the eyes (history of welding or similar activity)

  • Claustrophobia

  • Cardiac pacemaker or pacing wires

  • Pregnancy - Pregnancy tests will be offered to women of childbearing age at no cost to the subject

  • History of moderate to severe head injury, stroke, and seizures.

  • Alcoholism or drug dependency.

  • Renal or liver disease as this may cause concerns related to Gd-DTPA contrast agent.

  • Allergy to the contrast agent Gadolinium

  • Relapses or steroid therapy in patient at or in the month preceding the study

  • Patients only

Contacts and Locations

Locations

Site City State Country Postal Code
1 New York University School of Medicine New York New York United States 10016

Sponsors and Collaborators

  • NYU Langone Health

Investigators

  • Principal Investigator: Yulin Ge, MD, New York University Medical School

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
NYU Langone Health
ClinicalTrials.gov Identifier:
NCT03028675
Other Study ID Numbers:
  • 16-01434
First Posted:
Jan 23, 2017
Last Update Posted:
Jul 13, 2020
Last Verified:
Jul 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 13, 2020